Immunovant(IMVT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 • Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) • Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024) • Progressed Graves' dise ...